Loading
Cervical Cancer and HPV Research / Herpesvirus Infections and Treatments · Journal article
Multiple Sclerosis Journal · August 13, 2026
Well-designed and adequately powered for the question it asks.
This propensity-matched analysis of 115,522 women with MS found that those on disease-modifying therapies, particularly more immunosuppressive regimens, had significantly elevated risks of HPV positivity, cervical dysplasia, cervical cancer, cervicitis, herpes simplex virus positivity, vulvovaginitis, and Bartholin cysts/abscesses compared to those not on DMTs. The associations are consistent across outcomes, but the observational design limits causal attribution and does not establish whether DMTs are the direct cause or a marker of underlying immunologic differences.
Multicenter propensity-score 1:1 matched cohort study. Women with multiple sclerosis; propensity-matched cohorts enrolled from a multicenter database. Geography and specific eligibility criteria beyond MS diagnosis are not stated.. Intervention: Disease-modifying therapy (DMT) for multiple sclerosis; subset analysis of moderate- to high-immunosuppressive versus low-immunosuppressive DMTs.. Compared with: No DMT (primary comparison); low-immunosuppressive DMT (secondary comparison).. n = 115,522. Multicenter database; specific sites and countries not reported..
DMT use associated with HPV positivity (RR: 1.52, 95% CI: 1.35–1.72) DMT use associated with cervical dysplasia (RR: 1.40, 95% CI: 1.31–1.49) DMT use associated with cervical cancer (RR: 1.23, 95% CI: 1.03–1.46)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing women with MS should discuss potential gynecologic risks associated with DMT use, particularly with more immunosuppressive agents, and may intensify gynecologic screening and counseling accordingly. However, the observational design does not establish causation, and the decision to use or avoid DMTs should not be altered solely on the basis of these associations without evaluating MS disease control benefits.
Large propensity-matched observational cohort study with clear associations between DMTs and multiple gynecologic complications, reported with effect sizes and confidence intervals, but causal inference is limited by observational design.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing women with MS should discuss potential gynecologic risks associated with DMT use, particularly with more immunosuppressive agents, and may intensify gynecologic screening and counseling accordingly. However, the observational design does not establish causation, and the decision to use or avoid DMTs should not be altered solely on the basis of these associations without evaluating MS disease control benefits.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background/Objectives: The long-term implications of multiple sclerosis (MS) disease-modifying therapies (DMTs) on gynecologic health remain understudied. We leverage a multicenter database to evaluate whether DMTs are associated with such complications. Methods: We propensity-score 1:1 matched women with MS on (1) any versus no or (2) moderate- to high- (vs low-) immunosuppressive DMT by age, marital status, race, ethnicity, tobacco use, body mass index, human papilloma virus (HPV) vaccination, and gynecologic examinations/screenings. We then compared matched cohorts with risk ratios (RRs) and 95% confidence intervals (CIs). Results: After matching, we analyzed 115,522 women with MS. The DMT (vs no DMT) group had increased risks of HPV positivity (RR: 1.52, 95% CI: 1.35–172), cervical dysplasia (RR: 1.40, 95% CI: 1.31–1.49), cervical cancer (RR: 1.23, 95% CI: 1.03–1.46), cervicitis (RR: 1.25, 95% CI: 1.10–1.41), herpes simplex virus positivity (RR: 1.29, 95% CI: 1.14–1.45), vulvovaginitis (RR: 1.30, 95% CI: 1.23–1.37), and Bartholin cysts/abscesses (RR: 1.37, 95% CI: 1.07–1.76). Moderate- to high- (vs low-) immunosuppressive. Discussion: MS DMTs, especially more immunosuppressive ones, are associated with increased risks of several gynecologic complications. Clinicians should recognize these potential sequelae of DMTs and integrate gynecological counseling/screening into MS care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.